Although a state of ghrelin resistance appears to develop during end-stage renal failure, exogenous administration of ghrelin appears a promising therapeutic strategy to improve the clinical outcome of uremic patients. This evidence concerns the gene GHRL and stage 5 chronic kidney disease.